OTCMKTS:GNWSF StageZero Life Sciences (GNWSF) Stock Price, News & Analysis $0.0010 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About StageZero Life Sciences Stock (OTCMKTS:GNWSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GNWSF alerts:Sign Up Key Stats Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.00▼$1.27VolumeN/AAverage Volume26,719 shsMarket Capitalization$63.00 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview StageZero Life Sciences Ltd. is a Canadian life sciences company focused on developing and commercializing molecular diagnostic technologies for cancer detection. Its principal product is Aristotle, a blood-based test designed to analyze gene-expression patterns and identify signals associated with multiple types of cancer from a single blood sample. The company’s technology is intended to support earlier cancer screening and detection, potentially helping healthcare providers determine when additional diagnostic evaluation may be appropriate. StageZero has also pursued clinical validation and laboratory-based testing services related to its molecular diagnostics platform. StageZero Life Sciences is led by Dr. James Howard-Tripp, who serves as chief executive officer and chairman. The company is headquartered in Canada and has focused its development and commercialization efforts on bringing minimally invasive, multi-cancer screening technologies to healthcare markets.AI Generated. May Contain Errors. Read More Receive GNWSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNWSF Stock News HeadlinesStageZero Life Sciences Ltd.July 6, 2026 | marketwatch.comStageZero Announces Partial Revocation of Cease Trade Order and Proposed FinancingMay 9, 2025 | stockhouse.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 28 at 1:00 AM | Stansberry Research (Ad)Wave Life Sciences: Promising Growth with Strategic Innovations and Market ExpansionOctober 31, 2024 | markets.businessinsider.com5 things to know about the Texas Research Quarter, the life sciences hub planned for PlanoOctober 15, 2024 | msn.comChicago Beat: Looking at local life-sciences growth, Crafty gets new fundingOctober 11, 2024 | bizjournals.comNew Hampshire Life Sciences hosts Inaugural Live Free Life Science EventOctober 10, 2024 | yahoo.comHow Boy Meets World’s Ben Savage Views Maitland Ward's Porn CareerSeptember 25, 2024 | msn.comSee More Headlines GNWSF Stock Analysis - Frequently Asked Questions How have GNWSF shares performed this year? StageZero Life Sciences' stock was trading at $0.0005 at the beginning of the year. Since then, GNWSF stock has increased by 100.0% and is now trading at $0.0010. How do I buy shares of StageZero Life Sciences? Shares of GNWSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolOTCMKTS:GNWSF CIK1454263 Webwww.stagezerolifesciences.com Phone905-209-2030FaxN/AEmployees80Year Founded1998Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.86 million Net Margins-200.26% Pretax MarginN/A Return on EquityN/A Return on Assets-165.13% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.08 Sales & Book Value Annual Sales$4.15 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-0.05Miscellaneous Outstanding Shares62,995,000Free FloatN/AMarket Cap$63.00 thousand OptionableNot Optionable Beta0.28 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:GNWSF) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding StageZero Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share StageZero Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
